Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.
Research context
Chongqing Zhifei Biological Products Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Chongqing Zhifei Biological Products Co., Ltd is currently in a long term uptrend where the price is trading 7.4% above its 200 day moving average.
From a valuation standpoint, the stock is 116.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 20.8.
Chongqing Zhifei Biological Products Co., Ltd's total revenue rose by 38.9% to $4B since the same quarter in the previous year.
Its net income has increased by 61.4% to $974M since the same quarter in the previous year.
Finally, its free cash flow grew by 176.8% to $2B since the same quarter in the previous year.
Based on the above factors, Chongqing Zhifei Biological Products Co., Ltd gets an overall score of 4/5.